Business
ImmunoForge to Conduct Strategic Partnering at Bio-Europe Spring 2026
ImmunoForge Co., Ltd., a biopharmaceutical company developing treatments for rare diseases, announced that they will participate in Bio-Europe Spring 2026, held in Lisbon, Portugal, from March 23rd to 25th, 2026, to conduct strategic meetings with global pharmaceutical companies and investors.
About this update from Nh Investment & Securities Co.ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Conducting global licensing partnering of LMT15, a proprietary BBB Shuttle platform","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"Also discussing global out-licensing of Phase 2 stage new drugs PF1801 and PF1804","length":81,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":164,"olType":false},{"type":"text","content":"SEOUL, South Korea, March 12, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a biopharmaceutical company developing treatments for rare diseases, announced that they will participate in Bio-Europe Spring 2026, held in Lisbon, Portugal, from March 23rd to 25th, 2026, to conduct strategic meetings with global pharmaceutical companies and investors.","length":345,"tagName":"p"},{"type":"image","alt":"Immunoforge (PRNewsfoto/ImmunoForge)","displaySize":"","headline":null,"caption":"Immunoforge (PRNewsfoto/ImmunoForge)","className":"","disableSlideshowImg":false,"size":{"original":{"width":350,"height":350,"url":"https://media.zenfs.com/en/prnewswire.com/0b4eafa75902897d6e3c60fe5a89698a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0HFYqbT1A6M0kd8xR__J1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0b4eafa75902897d6e3c60fe5a89698a","width":350,"height":350}},"href":"https://mma.prnewswire.com/media/2596347/Immunoforge_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Instead of an official stage presentation, ImmunoForge plans to conduct meetings with overseas pharmaceutical companies by focusing on partnering sessions to discuss clinical progress and global technology transfer regarding its major development programs, PF1801 (in Phase 2) and PF1804 (Phase 2 approved).","length":312,"tagName":"p"},{"type":"text","content":"In addition to discussions on the ELP Platform, a long-acting technology that enables weekly or monthly administration of daily peptide-based drugs, the company plans to actively promote collaboration with global pharmaceutical companies by introducing its proprietary blood brain barrier (BBB)-penetrating Shuttle Platform, the LMT15 Platform technology.","length":360,"tagName":"p"},{"type":"text","content":"The LMT15 Platform is a differentiated platform that enables two modalities of drug development — BBB penetration and long-acting delivery — in a si...